Suzhou Teligene

Executive Summary

Suzhou Teligene is a clinical-stage Chinese biotech developing small molecule targeted therapies for oncology, with a focus on enhanced blood-brain barrier penetration to address brain metastases. The company's pipeline targets key oncogenic drivers including EGFR, HER2, NTRK, ROS1, and ALK mutations in solid tumors. Its lead asset is a brain-penetrant EGFR inhibitor currently in Phase 2 trials for NSCLC with brain metastases, differentiating from competitors through superior CNS exposure. With a strong scientific foundation and a clear unmet need in CNS oncology, Teligene is positioned for potential value inflection as it advances clinical development.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 clinical data for lead EGFR inhibitor in NSCLC brain metastases60% success
• Q4 2026IND filing for next-generation HER2 or NTRK inhibitor50% success
• H2 2026Potential strategic partnership or out-licensing deal for CNS pipeline40% success